HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders ...

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

Danish biotech company and obesity challenger Gubra AS (CSE: GUBRA) has announced this morning that it wants to treat its investors to a dividend of DKK 61 per share. An exercise that will cost Gubra ...

This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Following the most recent partnership on Gubra's Amylin drug candidate for obesity treatment in 2025, Gubra gained significant financial flexibility beyond its need to fund and realize its business ...

HØRSHOLM, DK / ACCESS Newswire / June 3, 2025 / Gubra (CPH:GUBRA) Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/SCVR NO. 30 51 40 41 To the shareholders ...

AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market.

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ABBV stock is a Strong Buy.